

Executive Education: September 27-28-29-30- October 1, 2021
10AM-12PM ET (New York) 4-6pm CAT (Johannesburg)

Topic: Effective ways to increase vaccination rates

For leaders, decision-makers, strategists and implementers of vaccination campaigns in Africa and the developing world.

[Register Here](#)

In the face of the Delta and Delta Plus variants, the lack of available COVID-19 vaccines in low- and middle- income countries pose a monumental problem. [Less than 5%](#) of Africans have received one or more doses of a COVID-19 vaccine, a percentage that lags a long way behind the world (32.9%) and far behind the United States (60.4%). As COVID-19 vaccine supply issues are slowly addressed, it is important to take steps to bolster public trust in vaccinations. In an [IPSOS](#) study 43% of Africans surveyed said they would definitely get vaccinated with a COVID-19 vaccine. In the same study, the primary reason for declining vaccines when they do become available was a lack of information about vaccines. In countries with vaccine surplus, many governments are moving forward with lotteries to attempt to boost vaccine uptake. Greatly concerning is that amidst the COVID-19 pandemic, the administration of standard childhood vaccines has declined. It is essential to address the reasons behind declining vaccination rates to find interventions to improve vaccine uptake for all diseases.

This executive education symposium is supported by the [Institute for Social and Economic Research and Policy](#) at Columbia, the [Program in Vaccine Education](#) at Columbia University's Vagelos College of Physicians and Surgeons, and the [Faculty of Health Sciences](#) at the University of the Witwatersrand.

Sept. 27: Current concerns with childhood vaccine uptake (Pg. 2)

Sept. 28: Addressing practical barriers is the best way to increase vaccination rates (Pg. 6)

Sept. 29: Vaccine hesitancy: what makes COVID-19 vaccines different? (Pg. 9)

Sept. 30: Trusted voices must be used to relay social norms (Pg. 14)

Oct. 1: Should the COVID-19 vaccine be mandated? In what circumstance? What incentives should be used? (Pg. 17)

Symposium Convenor: [Dr. Wilmot James](#), Senior Research Scholar, ISERP Columbia University

Symposium Coordinator: Harlowe Wang, Program Coordinator, ISERP Columbia University
 (contact iserp-events@columbia.edu)

September 27 - Day 1: Current concerns with childhood vaccine uptake

Vaccination rates for many diseases have been stalling, and COVID-19 has only exacerbated this problem by overwhelming healthcare workers and delaying non-emergency medical visits. From the [United States](#) to [Africa](#), studies have shown that childhood vaccination has been disrupted by the pandemic. Vaccine uptake is an issue that extends far beyond COVID-19 vaccines and must be urgently addressed to ensure that preventable illness and death is mitigated.



Moderator: **Dr. Shabir Madhi**
University of the Witwatersrand

Shabir Madhi is Professor of Vaccinology at the University of the Witwatersrand, Johannesburg, South Africa; and co-founder and co-Director of the African Leadership Initiative for Vaccinology Expertise (ALIVE). He currently also holds the positions of Director of the South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit (VIDA) and is Research Chair in

Vaccine Preventable Diseases of Department of Science and Technology/National Research Foundation. He is the National Principal Investigator and Protocol co-Chair of the first two COVID-19 vaccine studies being undertaken in South Africa.



Lecturer: **Dr. Lawrence Stanberry**
Columbia University

Dr. Stanberry is the Associate Dean for International Programs and Director of the Programs in Global Health at Columbia University's Vagelos College of Physicians and Surgeons. Previously he served as the Reuben S. Carpentier Professor and Chairman of the Department of Pediatrics at the Vagelos College of Physicians and Surgeons at Columbia University, and Pediatrician-in-Chief of the New York-Presbyterian/Morgan Stanley Children's Hospital (February 2008 – June 2018); the John Sealy Distinguished Professor and Chairman of Pediatrics and Director of the Sealy Center for Vaccine Development at the

University of Texas Medical Branch at Galveston (October 2000 – February 2008); and the Albert B. Sabin Professor of Pediatrics and Director of the Division of Infectious Diseases at the Cincinnati Children's Medical Center and University of Cincinnati College of Medicine (June 1995 – October 2000).

He has served on numerous advisory boards and review panels including serving as the chair of the Vaccine Study Section and the Pediatrics Review Panel at the National Institutes of Health.

He has received research funding from the National Institutes of Health, the Centers for Disease Control and Prevention, numerous vaccine, pharmaceutical and biotech companies, and the Bill and Melinda Gates Foundation. He is a pioneer in the areas of therapeutic vaccine development to control chronic viral diseases, topical microbicides/pre-exposure prophylaxis for the prevention of reproductive tract infections, and the development of herpes simplex virus and influenza virus vaccines. He has extensive experience in drug and vaccine development ranging from preclinical animal model studies through phase 3 multinational clinical trials.

Dr. Stanberry has authored over 200 scientific articles and chapters. He is the author of a book for the general public entitled, “Understanding Herpes” University Press of Mississippi, Jackson, Mississippi (1st edition 1998, 2nd edition 2006). He is the editor or co-editor of five textbooks including: “Genital and Neonatal Herpes” John Wiley and Sons, Ltd, London (1996), “Sexually Transmitted Diseases: Vaccines, Prevention, and Control” Academic Press, Ltd., London (1st edition 2000, 2nd edition 2012), “Vaccines for Biodefense and Emerging and Neglected Diseases, London, Elsevier (1st edition 2009, 2nd edition anticipated 2020). “Understanding Modern Vaccines” Elsevier (2011) and “Viral Infections of Humans: Epidemiology and Control,” (5th edition 2014, 6th edition anticipated 2020).

His current work focuses on the preparedness of children’s hospitals globally to prevent, detect, and respond to infections with pandemic potential.



Panelist: **Ms. Simone Carter**

IMOA, UNICEF Public Health Emergencies

Simone Carter is UNICEF’s lead on Integrated Multidisciplinary Outbreak Analytics for the Public Health Emergencies, where she provides support to countries to better integrate and operationalise evidence in outbreak response. Simone joined the Eastern DRC Ebola outbreak response in September 2018, where she, under the strategic coordination for the Ministry of Health (MOH), developed, set up, and managed the Social Sciences Analytics Cell (CASS), which is now operational in the DRC for Ebola, COVID and cholera. The DRC was the first time that such a structure has existed in outbreaks: providing real time social and behavioral analysis data in an integrated and coherent way to systematically influence the response and Simone is currently in Guinea Conakry working with WHO, CDC, MSF and the MoH to replicate this integrated analytics approach.

Simone has a Master of Science in Epidemiology from the University of British

Columbia's Faculty of Medicine where she focused her research on understanding HIV treatment attrition among sex workers. She has spent the last 10 years working across Latin America, sub-Saharan Africa and the Middle East in humanitarian response, six of which working for Oxfam's rapid response team leading the humanitarian and public health emergency response. Since the 2014-16 West Africa Ebola outbreak, Simone has focused on operational research to inform programming, aiming to improve accountability to communities through the use of evidence.

Simone leads the GOARN Analytics for Operations working group which aims to support different organizations and country teams in collaboration with academic, government and operational actors to ensure that integrated analytics are set up, coordinated and used to influence outbreak response. She is dedicated to ensuring that research and data are gender inclusive, using evidence for advocacy and raising the voices of women and children in public health emergencies.



Panelist: **Dr. Tanimola M. Akande**

University of Ilorin

Professor Tanimola Makanjuola AKANDE was born in 1960, he is a Professor of Public Health with University of Ilorin, Ilorin, Nigeria and a Consultant Public Health Physician with University of Ilorin Teaching Hospital. He is a specialist in Health Management. He studied Medicine at Ahmadu Bello University, Zaria where he graduated in 1984. He is a member West African College of Physicians and Nigerian Institute of Management (Chartered), a Fellow of the National Postgraduate Medical College. He was at various times Head, Department of Epidemiology & Community Health, University of Ilorin. He served in various Committees, Technical Working Groups and as Consultant to several international agencies and partners in and outside Nigeria. He was the National Chairman of Association of Public Health Physicians of Nigeria (APHPN) from 2013 – 2017. He was a member World Health Organization (WHO) African Region Technical Advisory Group (TAG) on Measles and Rubella. He is a Senior Researcher with Amsterdam Institute for Global Health and Development (AIGHD).

He is currently a member of Expert Review Committee (ERC) on Poliomyelitis Eradication Initiative and Routine Immunization in Nigeria, member Scientific Advisory Board, Vaccine Impact Modelling Consortium (VIMC), member Schmidt-Futures Vaccine Safety and Confidence-Building Working Group (VacSafe) and member of the Governing Council of Bingham University, Karu, Nigeria and member Governing Council of Thomas Adewumi University, Oko, Kwara State, Nigeria

He is also a member, Board of Trustees PharmAccess Foundation Nigeria; Board of Trustees Centre for Afri-Health Development; Board of Trustees African Civil Society for the Care and Support of Tuberculosis Patients (ACT). He is also a Member of Board of Directors, Josephine Consults and member of the Advisory Board of Exochos Innovations Limited.

He is a seasoned academic with over 180 publications in reputable peer reviewed local and international journals.



Panelist: **Dr. Marc Grodman**

Columbia University

Dr. Marc Grodman has been a leader in driving innovation in new critical areas of diagnostic testing. As the founder of BioReference in 1981, he oversaw unprecedented organic growth while fostering a culture of innovation and entrepreneurial spirit that led to the evolution of a small regional clinical laboratory into one of the largest clinical laboratories in the US with annual sales approaching \$1B. He also led GeneDx, a subsidiary of BioReference since 2006 to become world-renowned provider of genetic and genomics testing. BioReference was acquired by OPKO Health in June 2015. Throughout his career, Dr. Grodman has driven innovation in new critical areas of diagnostic testing, bringing clinically relevant information to physicians, as well as formatting data to enhance patient care and scientific advances. Leading a team of premier scientists, Dr. Grodman has created innovative programs in the areas of cancer, genetics and women's health. Dr. Grodman obtained his BA from the University of Pennsylvania, his MD from Columbia University College of Physicians and Surgeons, attended Harvard University's Kennedy School of Government, and was a Primary Care Clinical Fellow at Massachusetts General Hospital. Since 1983 he has served as an Assistant Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and serves on the Board of Advisors of the Columbia University Medical Center and was recently elected to the Board of Trustees at the New York Academy of Medicine. Dr. Grodman is the former Chairman and Director at the American Clinical Laboratory Association where he led the industry on numerous critical issues and served as a member of the Executive Committee of the Health Care Leadership Council where he was Chairman of the CEO Patient Safety and Quality Task Force.

September 28 - Day 2: Addressing practical barriers is the best way to increase vaccination rates

As demonstrated by the unacceptable vaccination rates across Africa, the greatest barriers to vaccination are those that are practical, such as a lack of supply. Other examples of practical barriers include long or arduous distances to clinics and onerous appointment booking systems. Removing practical barriers allows those who wish to get vaccinated – the majority of persons – to act on those motivations. Solutions to practical hurdles must be locally focused and context-specific to increase effectiveness.



Moderator: **Dr. Martin Veller**
University of the Witwatersrand

Martin Veller, MBBCh, FCS(SA), MMed(Surg), a vascular surgeon, is the past dean of the Faculty of Health Sciences of the University of the Witwatersrand (June 2014 to December 2020). Prior to this, he was the Professor and Head of the Department of Surgery, (November 2001 to February 2013) and the head of the Division of Vascular Surgery (January 1992 to June 2014).

His pre- and post-graduate training also occurred at the University of the Witwatersrand, where he qualified in general surgery in 1987. He subsequently undertook a vascular surgical research fellowship at the St. Mary's hospital, of the Imperial College, London (1990 to 1991). In April 2002, he was awarded an ad hominem professorship and became Professor Emeritus in January 2021.

He previously has been the Chairman of the Association of Surgeons, President of the World Federation of Vascular Societies, President of the Vascular Society of Southern Africa and President of the College of Surgeons of the Colleges of Medicine of South Africa.

Lecturer: **Ms. Amanda McClelland**
Resolve to Save Lives



Amanda McClelland, RN, MPH, is the Senior Vice President of Prevent Epidemics and Resolve to Save Lives at Vital Strategies where she leads a team working to accelerate progress to make the world safer from epidemics. Her achievements include coordinating frontline Ebola response during the 2014 Ebola

epidemic, for which she received the 2015 Florence Nightingale Medal for exceptional courage. Prior to joining Vital Strategies, McClelland served as the Global Emergency Health Advisor for the International Federation of Red Cross Red Crescent (IFRC) where she focused on emergency health, epidemic control, mass casualty in low resource settings, disease prevention and response operations.



Panelist: Dr. Clare Cutland

University of the Witwatersrand

Clare Cutland is the Scientific Coordinator of the African Leadership in Vaccinology Expertise (ALIVE) consortium, which is led by co-directors Professors Helen Rees (Wits RHI) and Shabir Madhi (VIDA/ RMPRU). ALIVE was selected as the flagship entity for the University of the Witwatersrand in 2016, and aims to create African expertise and leadership in vaccinology training, research and advocacy. She has established and coordinates the MSc(Med) in the field of vaccinology at Wits, and the 10-day African advanced vaccinology short course.

Prior to her appointment in ALIVE (Nov 2018), she was a research medical officer and subsequently the deputy director of the Respiratory and Meningeal Pathogens Research Unit (RMPRU, now Wits-VIDA), based at Chris Hani Baragwanath Academic Hospital (CHBAH), Soweto, South Africa (2000-2018).

She was an investigator on numerous phase I, II and III paediatric and maternal vaccine trials and principal investigator on a phase II paediatric measles vaccine trial, a phase III quadrivalent influenza vaccine trial in children and a phase III maternal influenza immunization trial in HIV-positive women.

Clare Cutland was the clinical lead for several large grant-funded neonatal sepsis prevention (PoPS, sepsis surveillance) and maternal immunization studies (influenza, *Streptococcus agalactiae* / Group B streptococcus sero-correlate of protection) and an investigator on numerous maternal immunization trials (GBS, RSV), and has published on challenges and lessons learnt in maternal immunization trials. She is national coordinator for the Oxford-AZ COVID-19 vaccine trial in South Africa (April 2020 – current), being led by Shabir Madhi, and is a sub-investigator on Oxford-Astra Zeneca- and Novavax COVID-19 vaccine trials

She was involved in the GAIA Brighton collaboration definition working groups (2014-2016), and was elected as a member of the scientific board of the Brighton collaboration in 2018 (to present). She is a member of the Wits Institutional biosafety committee and working group for maternal COVID-19 vaccines. She is author or co-author on over 80 peer-reviewed journal articles.

Panelist: **Dr. Raji Tajudeen**

Africa Centres for Disease Control and Prevention



Raji Tajudeen MD, MPH, FWACP, is a Medical Doctor with postgraduate qualifications in Pediatrics and Public Health. He is a Fellow of the West African College of Physicians and African Public Health Leaders Fellow of the Chatham House Royal Institute of International Affairs, UK. He has years of senior level experience in Child Health, Health System Management, Health Diplomacy, Maternal and Child Health, and Health in Humanitarian Emergencies. He has worked in different settings in the developing world; Nigeria, Saudi Arabia, Liberia, Guinea, Sierra Leone and Ethiopia.

He is currently the Head of Public Health Institutes and Research at the Africa Centres for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia. He coordinates the establishment and strengthening of National Public Health Institutes across the 55 African Union Member States. He oversees the establishment of the five Africa CDC Regional Collaborating Centers in Lusaka, Abuja, Libreville, Nairobi and Cairo. He coordinates the Africa CDC Institute for Workforce Development and the public health research agenda.

Taj heads the healthcare preparedness and countermeasures section of the Africa CCD COVID-19 response. He co-chairs the case management technical working group of the Africa Taskforce on COVID-19.

Panelist: **Dr. Ronald Whelan**

Discovery Health



Dr Ronald Whelan is Chief Commercial Officer of Discovery Health. A medical doctor by training with an MBA, he was Associate Partner at McKinsey from 2006 to 2013 during which time he co-led McKinsey's healthcare practice across sub-Saharan Africa.

From 2013 to 2019 he was Partner and Head of Healthcare Investments at Spinnaker Growth Partners where he led investments and business development across a range of healthcare ventures and was founder of Healthforce, a leading telemedicine player in South Africa.

Dr Whelan has extensive experience in clinical and corporate healthcare spanning more than 20 years and 25 countries globally.


September 29 - Day 3: Vaccine hesitancy: what makes COVID-19 vaccines different?

In 2019, the WHO announced that vaccine hesitancy – an expression used to encompass a multitude of reasons for why a lack of vaccination occurs despite the availability of vaccines – was a top 10 threat to global health. As fears around COVID-19 vaccine safety coupled with fears around the rise of the anti-vax movement, vaccine hesitancy became a phrase that is used commonly by scientists and the public alike. Due to the immediate threat of the SARS-CoV-2 virus and the rapid development of COVID-19 vaccines, COVID-19 vaccine hesitancy is a notable issue worthy of addressing. It is important to focus on the "wait and see" group, made up of persons who wish to see vaccine safety and efficacy on others before they themselves get vaccinated. Studies have shown that efforts to directly challenge those who are skeptical towards vaccines do not increase vaccination rates. Rather than concentrating on disputing misinformation, energy should be focused on amplifying positive and accurate vaccine content.



Moderator: **Dr. Anya Schiffrin**
Columbia University

Anya Schiffrin is the director of the Technology, Media, and Communications at Columbia University's School of International and Public Affairs and a lecturer who teaches on global media, innovation and human rights. She writes on journalism and development, investigative reporting in the global south and has published extensively over the last decade on the media in Africa. More recently she has become focused on solutions to the problem of online disinformation, earning her PHD on the topic from the University of Navarra. She is the editor of *Global Muckraking: 100 Years of Investigative Reporting from Around the World* (New Press, 2014) and *African Muckraking: 75 years of Investigative journalism from Africa* (Jakana 2017). She is the editor of the forthcoming *Media Capture: How Money, Digital Platforms and Governments Control the News* (Columbia University Press 2020)



Lecturer: **Dr. Peter Hotez**
Baylor College of Medicine

Peter J. Hotez, M.D., Ph.D. is Dean of the National School of Tropical Medicine and Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also the Co-director of the Texas Children's Center for Vaccine Development (CVD) and

Texas Children's Hospital Endowed Chair of Tropical Pediatrics. He is also University Professor at Baylor University, Fellow in Disease and Poverty at the James A Baker III Institute for Public Policy, Senior Fellow at the Scowcroft Institute of International Affairs at Texas A&M University, Faculty Fellow with the Hagler Institute for Advanced Studies at Texas A&M University, and Health Policy Scholar in the Baylor Center for Medical Ethics and Health Policy.

Dr. Hotez is an internationally-recognized physician-scientist in neglected tropical diseases and vaccine development. As head of the Texas Children's CVD, he leads a team and product development partnership for developing new vaccines for hookworm infection, schistosomiasis, leishmaniasis, Chagas disease, and SARS/MERS/SARS-2 coronavirus, diseases affecting hundreds of millions of children and adults worldwide, while championing access to vaccines globally and in the United States. In 2006 at the Clinton Global Initiative he co-founded the Global Network for Neglected Tropical Diseases to provide access to essential medicines for hundreds of millions of people

He obtained his undergraduate degree in molecular biophysics from Yale University in 1980 (phi beta kappa), followed by a Ph.D. degree in biochemistry from Rockefeller University in 1986, and an M.D. from Weil Cornell Medical College in 1987. Dr. Hotez has authored more than 500 original papers and is the author of four single-author books, including *Forgotten People, Forgotten Diseases* (ASM Press); *Blue Marble Health: An Innovative Plan to Fight Diseases of the Poor amid Wealth* (Johns Hopkins University Press); *Vaccines Did Not Cause Rachel's Autism* (Johns Hopkins University Press); and a forthcoming 2020 book on vaccine diplomacy in an age of war, political collapse, climate change and antiscience (Johns Hopkins University Press).

Dr. Hotez served previously as President of the American Society of Tropical Medicine and Hygiene and he is founding Editor-in-Chief of PLoS Neglected Tropical Diseases. He is an elected member of the National Academy of Medicine (Public Health Section) and the American Academy of Arts & Sciences (Public Policy Section). In 2011, he was awarded the Abraham Horwitz Award for Excellence in Leadership in Inter-American Health by the Pan American Health Organization of the WHO. In 2014-16, he served in the Obama Administration as US Envoy, focusing on vaccine diplomacy initiatives between the US Government and countries in the Middle East and North Africa. In 2018, he was appointed by the US State Department to serve on the Board of Governors for the US Israel Binational Science Foundation, and is frequently called upon frequently to testify before US Congress. He has served on infectious disease task forces for two consecutive Texas Governors. For these efforts in 2017 he was named by FORTUNE Magazine as one of the 34 most influential people in health care, while in 2018 he received the Sustained Leadership Award from Research!America. In 2019 he received the Ronald McDonald House Charities Award for Medical Excellence

Most recently as both a vaccine scientist and autism parent, he has led national efforts to defend vaccines and to serve as an ardent champion of vaccines going up against a growing national "antivax" threat. In 2019, he received the Award for Leadership in Advocacy for Vaccines from the American Society of Tropical Medicine and Hygiene. Dr. Hotez appears

frequently on television (including BBC, CNN, Fox News, and MSNBC), radio, and in newspaper interviews (including the New York Times, USA Today, Washington Post, and Wall Street Journal).



Panelist: Dr. Sara Cooper

South Africa Medical Research Council and University of Cape Town

Dr Sara Cooper is a Senior Scientist in Cochrane South Africa at the South African Medical Research Council. She holds a Bachelor's (Honours) degree in Psychology and a Master's in Public Health from the University of Cape Town (UCT) and a PhD in medical sociology from the London School of Hygiene & Tropical Medicine. Her research interests include the application and explanatory potential of social science theories and methodologies within health research, policy and practice, and how qualitative health research can be both 'critical' and 'applied'. Her previous research focused on these issues in the realm of long-term chronic illnesses, including mental illness, HIV/AIDS, diabetes and obesity. Her most current research is exploring these issues in the field of vaccine research, particularly around vaccine intentions, behaviours and decision-making in Africa, and the emerging methodology of qualitative evidence synthesis (QES). Sara has extensive experience in conducting and building capacity for critical qualitative health research in sub-Saharan Africa (SSA), having worked on as a senior qualitative researcher on a number of global public health projects. Highlights include the DFID-funded Mental Health and Poverty Project (MHaPP) which examined mental health systems in SSA; the NIH-funded study which explored experiences of mental illness in people living with HIV in Zimbabwe (the TENDAI study); and the UKMRC-funded Formative and Process Evaluation study of an RCT evaluating the effectiveness of an mHealth intervention to support treatment adherence for people with type-2 diabetes in SSA (StAR2D study). Sara is also an Honorary researcher in the Division of Social & Behavioural Sciences in the School of Public Health at UCT and on the editorial board of Critical Public Health. She is also currently a member of the Vaccine Hesitancy Working Group within the South African National Advisory Group on Immunisation (NAGI) and the Vaccine Hesitancy Technical Working Group within the Ministerial Advisory Committee (MAC) on COVID-19.



Panelist: Dr. Susan Rosenthal

Columbia University

Susan L. Rosenthal, PhD, is a Professor of Medical Psychology (in Pediatrics and Psychiatry) at Columbia University Vagelos College of Physicians and Surgeons. She is Vice Chair for Faculty Development as well as Chief of the Division of Child and Adolescent Health in the Department of Pediatrics. Dr. Rosenthal has over 30 years' experience as a pediatric psychologist and is an accomplished researcher in the areas of adolescent health, promotion of sexual health, vaccine acceptability, and the acceptability of microbicides.

Dr. Rosenthal received her BA from Wellesley College and her PhD from the University of North Carolina at Chapel Hill. She completed an internship at the University of Maryland and did her postdoctoral training at the Yale Child Study Center. Her first faculty appointment was at Cincinnati Children's Hospital. Dr. Rosenthal later served on the faculty at the University of Texas Medical Branch at Galveston, where she was Director of the Division of Adolescent and Behavioral Health and Director of the Pediatric Department's Office of Faculty Development.

Throughout her career, Dr. Rosenthal has focused on applying psychological and developmental knowledge to the promotion of sexual health as well as the acceptability and implementation of new biomedical interventions that prevent acquisition of sexually transmitted infections (STIs). Her work has included both qualitative and quantitative methodologies. Dr. Rosenthal's research has been funded by the National Institutes of Health, the Center for Disease Control, industry, and foundations. She has served as an advisor to the World Health Organization regarding the implementation of the HPV vaccine in developing countries. Dr. Rosenthal has published over 250 publications.

In 2009, Dr. Rosenthal was recruited to Columbia to serve as the Vice Chair for Faculty Development in the Department of Pediatrics. In this role, she developed and implemented a faculty development program designed to enable faculty to achieve career advancement and professional satisfaction. She has presented at local and national meetings and published on her work in faculty development. Particular areas of focus pertaining to faculty development include mentoring relationships, leadership development, and wellness/burnout prevention.

As Chief of the Division of Child and Adolescent Health since 2011, Dr. Rosenthal has overseen the growth of existing programs and the addition of new programs including the creation of a monitored unit, an insurance-based adolescent outpatient program, and a complex care program.



Panelist: **Dr. Stavros Nicolaou**

Aspen Pharmacare

Stavros Nicolaou is the Aspen Pharmacare Group's Senior Executive responsible for Strategic Trade Development. Previously he was CEO of Aspen's Export Business. Aspen is Africa's largest pharmaceutical manufacturer and a now world leader in Anaesthetics and injectable anti-coagulants. Aspen is one of South Africa's most globalised multinational companies with a presence in over 50 geographies globally, with 26 manufacturing facilities across 6 continents. He was instrumental in introducing the first generic ARV's on the African Continent developed by Aspen, which has gone on to save hundreds of thousands of lives in South Africa and on the African Continent.

Nicolaou has over 28 years' experience in the South African and International Pharmaceutical Industry and is a previous winner of the SA Institute of Marketing Management (IMM) Health Care Marketer of the year Award. He was inducted as one of the youngest Fellow of the Pharmaceutical Society of South Africa (PSSA), one of the highest honours bestowed by the PSSA, and was recently awarded an Honorary Doctorate of Science in Medicine from Wits University.

September 30 - Day 4: Trusted voices must be used to relay social norms

Though there is variation internationally, current data suggests that recommendations from health workers carry the most weight in increasing vaccination rates. Simple adjustments in the language used to convey advice to patients can produce significant improvements in vaccination rates. Local norms and practices must always be taken into consideration in establishing efficacious communication that boosts vaccine uptake. For instance, community-level leaders may prove most effective in some cultures.



Moderator: **Dr. Wilmot James**

Columbia University

Wilmot James is a Senior Research Scholar at the Institute for Social and Economic Research and Policy (ISERP), College of Arts and Sciences, Columbia University. An academic by background with a Ph.D. from the University of Wisconsin at Madison, he was previously a Member of Parliament (South Africa) and opposition spokesperson on health. Dr. James is currently serves as Member of the Accessible Medicines Advisory Board of Chimeron Bio; Member of the Board: Resolve to Save Lives; and Co-Chair of the G7 National Frameworks Working Group -

Global Partnership - Africa Signature Initiative on Biosecurity.

Wilmot is the author and/or editor of 17 books that include the policy-oriented *Vital Signs: Health Security in South Africa* (2020), a set of essays on the public understanding of science titled *Nature's Gifts: Why we are the way we are* (2010), a coedited book *Biotechnology and Health: South Africa's aspirations in health-related biotechnology* (2007) and a co-edited collection of Nelson Mandela's presidential speeches *Nelson Mandela In His Own Words* (2003), the latter having the distinction of containing forwards by Bill Clinton and Kofi Annan and given to the late Nelson Mandela on his 85th birthday. Dr. James served on the Board of Trustees of the Ford Foundation between 1996-2008. He has teaching experience from the University of the Western Cape and University of Cape Town and post-doctoral and visiting professorial experience from Yale University, Indiana University, Edinburgh University and the California Institute of Technology.

At Columbia University, he teaches a (spring) course on Pandemics, Ethics and Governance at the School for Professional Studies, conducts research on children's health security with Drs. Larry Stanberry and Philip LaRussa in the Department of Pediatrics, Vagelos College of Physicians and Surgeons, and convenes high-level meetings on planetary and catastrophic risks. Wilmot serves as a senior consultant in biosecurity to the Washington DC based Nuclear Threat Initiative.



Lecturer: **Dr. Tariro Makadzange**
Stanford University

Tariro Makadzange is an Infectious diseases and Viral/Vaccine immunologist. She earned a BA at Smith College, an MD at Harvard Medical School and a D.Phil from Oxford University. Dr. Makadzange trained in Internal Medicine at the University of Washington and Infectious Diseases at Massachusetts General Hospital where she later joined the faculty. Her research has focused on HIV immunology, clinical trials and implementation science. She has been engaged in training and mentoring HIV clinicians and researchers and co-established one of the largest HIV treatment programs in Zimbabwe. She has worked in industry and academia in early and late phase clinical trials, and vaccine development.



Panelist: **Dr. Janan Dietrich**
University of the Witwatersrand

Dr Janan Dietrich started at the Perinatal HIV Research Unit (PHRU) in 2007 as a Social Scientist and progressed to become a Director of the Biobehavioural Research Centre at the PHRU. Additionally, she is an Associate Researcher at the University of the Witwatersrand, a consulting social science expert for the HIV Vaccine Trials Network (HVTN) and an investigator of the Canada-Africa Prevention Trials Network. Her experience in leading socio-behavioral research extends to HIV prevention, treatment and care with both adult and adolescent populations. In 2008, she initiated the Adolescent Community Advisory Board (CAB) at the PHRU and facilitated their initial training and development. She has mentored multiple students. In 2010 Janan Dietrich received a Leader of Tomorrow Award in the category of medical and auxiliary science by the Most Influential Women in Business and Government awards by CEO magazine, South Africa. In 2013 Janan Dietrich received prestigious awards from the University of the Witwatersrand, the Harvard Centre for AIDS research and the National Research Foundation of South Africa.



Panelist: **Dr. Hassan Mohamed**

Western Cape Department of Health

Qualifications: MBChB, MMed (Community Health) PhD (Public Health).

Prof Hassan Mahomed works currently as a Public Health Medicine specialist at the Western Cape Government Dept of Health and Division of Health Systems and Public Health in the Department of Global Health at Stellenbosch University. In the Department of Health, he provides technical support for planning, monitoring and evaluation, health systems reform, health information systems development and outbreak response. He has played a key role in co-ordinating the province's response to the COVID-19 epidemic including the vaccine rollout. At Stellenbosch University, he teaches public health and runs a clinical trials module. He supervises both masters and PhD students.



Panelist: **Dr. Jonathan Stryko**

*Children's Hospital of Philadelphia (CHOP), and
Botswana-University of Pennsylvania Partnership (BUP)*

Jonathan Stryko is the Children's Hospital of Philadelphia (CHOP) David N. Pincus Global Health Fellow based full-time in Gaborone, Botswana. He completed his pediatric and chief residency training at Maimonides Infants and Children's Hospital of Brooklyn and spent two years at Centers for Disease Control and Prevention as an Epidemic Intelligence Service officer in the National Center for Enteric and Zoonotic Infectious Diseases. Based in Botswana since 2019, he has been heavily involved in the COVID-19 response, serving on the national pediatric task force while continuing clinical service at Princess Marina Hospital and teaching at University of Botswana's Faculty of Medicine. His research focuses on antimicrobial resistance, waterborne diseases, infant feeding, and neonatal sepsis.

**October 1 - Day 5: Should the COVID-19 vaccine be mandated? In what circumstance?
What incentives should be used?**

10:00am - 12:30pm ET | 4:00pm - 6:30pm CAT

Is it a violation of personal autonomy to require someone to receive a vaccination? As getting vaccinated protects society, is it within legal and ethical bounds to mandate that an employee or healthcare provider or student receives a vaccine? Are the COVID-19 vaccines different from other vaccines? Lastly, what incentives work (and what incentives are morally acceptable) in encouraging people to get vaccinated?



Moderator: **Dr. Philip LaRussa**

Columbia University, New York City, USA

Dr. Philip LaRussa is a pediatric infectious disease specialist with four decades of experience in clinical and epidemiological infectious diseases research in local and global settings. He received an M.D. degree from the Università degli Studi in Bologna, Italy in 1978, completed residency training in Pediatrics (1978-1981), and a fellowship training in pediatric Infectious diseases (1981-1981) at New York University-Bellevue Hospital Medical Center, New York. He was an Assistant Professor of Pediatrics, New York University School of Medicine,

Department of Pediatrics, Division of Infectious Diseases, in New York from 1983-1986. From 2000-2019, he was Professor of Pediatrics at Columbia University School of Medicine, and since 2019, he is emeritus Professor of Pediatrics at the same institution.

His research interests include the pathogenesis, immune response, diagnosis, treatment, and prevention of varicella zoster virus infections in children. He developed the first PCR assay to distinguish varicella vaccine virus from wild-type strain, which allowed the accurate differentiation of adverse events due to the vaccine from complications of wild-type infection, and described the effectiveness of varicella vaccine in healthy and immunocompromised hosts. He also described important co-factors influencing the perinatal transmission of HIV and outcomes of perinatally infected infants. He was the principal investigator for the Women and Infants Transmission Study (WITS IV: 2001-2007), and of the NIH-funded International Maternal Pediatric Adolescent Clinical Trials site at Columbia University Medical Center and director of its the on-site retrovirus study laboratory from 2006-2013. Since 2001, his research has focused on immunization safety issues, and has been the Principal Investigator for the CDC-funded Clinical Immunization Safety Assessment (CISA) Center at Columbia University Medical Center. During the last ten years he has also focused on capacity assessment, and capacity building research projects in sub-Saharan Africa, and has recently completed a study of

capacity in 24 hospitals that care for children in sub-Saharan Africa.

He has been a member of numerous national and international advisory committees including the Brighton Collaboration Working Group for development of case definitions for smallpox vaccine associated adverse events (2003-2005), the Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices, Subcommittee on varicella vaccination (2004-2006), the F.D.A. Advisory Committee on Vaccines & Related Biological Products (2004 – 2008), Chair of the NIH NIAID Influenza Research Collaboration (NIRC) Combination Therapy Focus Group (2009 – 2010), Member, U.S. Dept. of Health & Human Services, National Vaccine Advisory Committee [NVAC] (2011 – 2015), Co-chair, U.S. Dept. of Health & Human Services, National Vaccine Advisory Committee (NVAC) Global Immunization Working Group (2012-2014), Member, W.H.O. Strategic Advisory Group of Experts on Immunization Working Group on Varicella & Zoster vaccines (2012 – 2014), and Member, F.D.A., Pediatric Advisory Committee (2012 – 2016). He is the author of 164 peer-reviewed scientific papers, and 28 chapters in textbooks.



Lecturer: **Dr. Wafaa El-Sadr**

Columbia University, New York City, USA

Wafaa El-Sadr, MD, MPH, MPA is a University Professor of Epidemiology and Medicine at Columbia University, the director of ICAP at Columbia University, and director of the Global Health Initiative at the Mailman School of Public Health.

Founded by Dr. El-Sadr, ICAP is a global leader in HIV, other global health threats, and health systems strengthening that provides technical assistance, implementation support, and conducts research in

partnership with governmental and non-governmental organizations in more than 21 countries. In this role, she leads the design, implementation, scale-up, and evaluation of large-scale HIV, tuberculosis (TB) and maternal-child health programs in sub-Saharan Africa and Asia that provide access to HIV services to more than 2.2 million people and collect data from more than 5,200 health facilities.

Dr. El-Sadr is a prominent researcher and has led numerous epidemiological, clinical, behavioral, and implementation science research studies that have furthered the understanding of the prevention and management of HIV, TB, and non-communicable diseases. She is a principal investigator of the NIH-funded HIV Prevention Trials Network (HPTN), which seeks to prevent HIV transmission, globally.

Dr. El-Sadr is a member of the NIH Fogarty International Center Advisory Board. In 2008, she was named a John D. and Catherine T. MacArthur Foundation Fellow, and in 2009, she

was appointed to the National Academy of Medicine. In 2013, she was appointed University Professor, Columbia's highest academic honor. She also holds the Dr. Mathilde Krim-amfAR Chair in Global Health.



Panelist: **Dr. Helen Rees**

University of the Witwatersrand

Professor Helen Rees is Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand in Johannesburg where she is also a Personal Professor in Obstetrics and Gynaecology, and Co-Director of the Wits African Local Initiative for Vaccinology Expertise (ALIVE). She is an Honorary Professor at the London School of Hygiene and Tropical Medicine in the Faculty of Tropical and Infectious Diseases, an Honorary Fellow at Murray Edwards College, Cambridge University, and an alumna of Harvard Business School. Helen is internationally renowned for her research and policy work in HIV, vaccines, reproductive health and drug regulation.



Panelist: **Dr. Keymanthri Moodley**

Stellenbosch University

Keymanthri Moodley is a Distinguished Professor in the Department of Medicine and Director of the Centre for Medical Ethics and Law, Faculty of Health Sciences, Stellenbosch University. In 2017, she was appointed as Adjunct Professor in the Department of Social Medicine, University of North Carolina-Chapel Hill, USA. Keymanthri is a specialist family physician, bioethicist and has served as a Principal Investigator on clinical trials.

She is an NRF rated researcher and has served on the SAMRC Board and the NHREC and in international organisations: WHO, International AIDS Society (IAS), NIH DSMBs, the WHO SAGE Ebola Working Group and various WHO COVID ethics working groups. The Centre was re-designated as a Collaborating Centre in Bioethics in 2019 by the WHO, one of twelve in the world and the first on the African continent.

Keymanthri is a member of the Academy of Science of South Africa and completed an Executive MBA in 2015. To date, she has been awarded research and capacity development grants to the approximate value of R40 million. The Centre has trained 40 mid-career

professionals from 10 African countries in bioethics and is currently co-presenting an NIH funded Leadership program in Bioethics with 7 PhD trainees. Keymanthri serves on the Scientific Advisory Committee of EDCTP, Netherlands and has served on the Science and Research Working Group of the International Paralympic Committee, Bonn, Germany.



Panelist: **Mr. Halton Cheadle**
[Emeritus] University of Cape Town

Halton Cheadle is an attorney with 40 years' experience. His areas of expertise include labour law, constitutional law, administrative law and municipal law.

He also has extensive experience in legislative drafting and has participated in the drafting of the Bill of Rights in the final Constitution, various labour statutes including the Labour Relations Act, 1995, the National Economic Development and Labour Council Act, 1994 and the Mine Health and Safety Act,

1996. He recently drafted the Minimum Wage Act, as well as the amendments to the Labour Relations Act and the Code of Good Practice: Collective Bargaining, Industrial Action & Picketing and the Accord on Collective Bargaining & Industrial Action.

He has also participated in the drafting of other laws such as the Special Pensions Bill, the Electoral Bill, and the Public Administration Management Bill, 2014. He has also drafted labour laws as part of labour law reform in Botswana, Lesotho, Mozambique, Namibia, Swaziland, Tanzania, Nigeria and Zimbabwe.

Halton has also been involved as author and editor of various books and journal articles on labour and constitutional law.

He has been an acting judge in the High Court and the Labour Court and has experience as an arbitrator.

Halton is the first South African to sit on the ILO Committee of Experts on the Application of Conventions and Recommendations (CEACR), International Labour Organisation, Geneva.

He is an Emeritus Professor of Public Law at the University of Cape Town.

Closing Reflections:



Mr. Joshua Nott

Schmidt Futures

Joshua Nott is an Associate at Schmidt Futures where he works on institutional strategic planning, the implementation and evaluation of priority projects, budgeting, and talent management. Joshua joined Schmidt Futures from the Rhodes Trust where he worked on the establishment of Rise. A native of South Africa, Joshua is passionate about African public policy challenges with a particular interest in Southern and East African development and integration. His policy experience includes time with the Global Economic Governance Programme at Oxford University's Blavatnik School of Government, the Institute of African Alternatives in Cape Town, and the Center for Strategic and International Studies, Washington D.C.

Joshua holds a Masters of Public Policy (with Distinction) and an MSc in African Studies from the University of Oxford where he studied as a Rhodes Scholar. While at Oxford, Joshua represented the University's Men's Water Polo team achieving his Oxford Blues. In addition to his postgraduate qualifications, Joshua holds a Bachelor of Laws (with Distinction) and a Bachelor of Social Science (with Distinction in Political Studies) from the University of Cape Town.



Mr. Mark Heywood

Daily Maverick

Mark Heywood is the Editor of Maverick Citizen, a section of the Daily Maverick. He is the former Executive Director of SECTION27 and has been a human rights activist most of his life.